Spanish pharmaceutical company Grifols said on Monday it agreed to buy plasma assets in North America from South Korea’s Green Cross for $460 million.
Grifols will buy a plasma fractionation plant in Canada and two purification facilities and 11 plasma collection centres in the United States, the company said in a statement.
The Barcelona-based firm will need no new financing to carry out the acquisition, it said.
Grifols is one of the world’s top producers of treatments based on human plasma.
Source: Reuters.com